Supporting this, the odds ratio for persistence in the HPV 16/18 group increased to 1.05 among vaccinated individuals aged 27–39 years, although this difference did not reach statistical significance.
← all excerpts
Effectiveness of the Human Papillomavirus Vaccine in Extended Age Groups: A Real-World Analysis Based on the Korean HPV Cohort Study.
1
—
—